Notice of Establishment, 47503 [06-6966]

Download as PDF Federal Register / Vol. 71, No. 159 / Thursday, August 17, 2006 / Notices electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the full title of the draft guidance document and the docket number found in brackets in the heading of this document. A copy of the draft guidance and received comments are available for public examination in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. V. Electronic Access Electronic comments may be submitted on the Internet at https:// www.fda.gov/dockets/ecomments. Once on the Internet site, select Docket No. 2006D–0301, ‘‘Animal Drug User Fees; Fees Exceeds Costs Waivers and Reductions’’ and follow the directions. A copy of this document may be obtained on the Internet from the CVM home page at https://www.fda.gov/cvm. Dated: August 10, 2006. Jeffrey Shuren, Assistant Commissioner for Policy. [FR Doc. E6–13507 Filed 8–16–06; 8:45 am] BILLING CODE 4160–01–S DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Notice of Establishment rwilkins on PROD1PC63 with NOTICES Pursuant to the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), the Director, National Institutes of Health (NIH), announces the establishment of the NIH Office of Portfolio Analysis and Strategic Initiatives (OPASI) Council of Councils (Council). The Council will consult with, and provide advice and recommendations to the Director NIH, the Director, OPASI, and the individual Institute and Center (IC) Directors on potential trans-NIH initiatives at the conceptual stage. The Council’s advice and recommendations will assist the IC Directors in identifying trans-NIH initiatives to be pursued for further development. Duration of this committee is two years from the date the Charter is filed. Dated: August 8, 2006. Elias Zerhouni, Director, National Institutes of Health. [FR Doc. 06–6966 Filed 8–16–06; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institutes of Health National Cancer Institute; Notice of Meeting National Cancer Institute; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Cancer Institute Director’s Consumer Liaison Group. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the National Cancer Advisory Board. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4), and 552b(c)(6), as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Director’s Consumer Liaison Group. Date: October 25, 2006. Time: 7:30 a.m. to 6 p.m. Agenda: (1) Meeting with NCI Acting Director; (2) Updates on NCI Programs; (3) Update on NCI Budget and Legislation; Report from NCI Listens and Learns Working Group and DCLG Summit Working Group; (4) Public Comment; (5) Action Items and Conclusion. Place: National Institutes of Health, Natcher Building, 45 Center Drive, Bethesda, MD 20892. Contact Person: Barbara Guest, Executive Secretary, Office of Liaison Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Blvd., Room 2202, Rockville, MD 20892–8324, 301–496–0307, guestb@mail.nih.gov. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s/Center’s home page: https:// deainfo.nci.nih.gov/advisory/dclg/dclg.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS). Dated: August 8, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–6963 Filed 8–16–06; 8:45 am] BILLING CODE 4140–01–M VerDate Aug<31>2005 16:36 Aug 16, 2006 Jkt 208001 47503 PO 00000 Frm 00025 Fmt 4703 Sfmt 4703 Name of Committee: National Cancer Advisory Board. Open: September 6, 2006, 8:30 a.m. to 4:15 p.m. Agenda: Program reports and presentations; Business of the Board. Place: National Cancer Institute, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892. Contact Person: Dr. Paulette S. Gray, Executive Secretary, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, 8th Floor, Room 8001, Bethesda, MD 20892–8327, (301) 496–5147. Name of Committee: National Cancer Advisory Board. Closed: September 6, 2006, 4:15 p.m. to 5:15 p.m. Agenda: Review of grant applications. Contact Person: Dr. Paulette S. Gray, Executive Secretary, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, 8th Floor, Room 8001, Bethesda, MD 20892–8327, (301) 496–5147. Name of Committee: National Cancer Advisory Board. Open: September 7, 2006, 8 a.m. to 12 p.m. Agenda: Program reports and presentations; Business of the Board. Contact Person: Dr. Paulette S. Gray, Executive Secretary, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, 8th Floor, Room 8001, Bethesda, MD 20892–8327, (301) 496–5147. Any interested person may file written comments with the committee by forwarding E:\FR\FM\17AUN1.SGM 17AUN1

Agencies

[Federal Register Volume 71, Number 159 (Thursday, August 17, 2006)]
[Notices]
[Page 47503]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Notice of Establishment

    Pursuant to the Federal Advisory Committee Act, as amended (5 
U.S.C. Appendix 2), the Director, National Institutes of Health (NIH), 
announces the establishment of the NIH Office of Portfolio Analysis and 
Strategic Initiatives (OPASI) Council of Councils (Council).
    The Council will consult with, and provide advice and 
recommendations to the Director NIH, the Director, OPASI, and the 
individual Institute and Center (IC) Directors on potential trans-NIH 
initiatives at the conceptual stage. The Council's advice and 
recommendations will assist the IC Directors in identifying trans-NIH 
initiatives to be pursued for further development.
    Duration of this committee is two years from the date the Charter 
is filed.

    Dated: August 8, 2006.
Elias Zerhouni,
Director, National Institutes of Health.
[FR Doc. 06-6966 Filed 8-16-06; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.